Q-omics provides the consensus-scored HNRNPA1P73 profile across patient tissues and cancer cell-line models. HNRNPA1P73 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, HNRNPA1P73 is differentially expressed in 4, with the highest sampling consensus in BRCA. Additionally, HNRNPA1P73 RNA expression shows 6,334 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight LIHC, BRCA, and STAD as cancer lineages where HNRNPA1P73 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HNRNPA1P73 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HNRNPA1P73 survival associations across molecular data types. HNRNPA1P73 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HNRNPA1P73 RNA expression–survival associations across cancer types. High HNRNPA1P73 expression shows unfavorable associations in LIHC, STAD, KIRP, CHOL and LUAD, but favorable associations in BLCA. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for HNRNPA1P73 RNA expression.
This table summarizes HNRNPA1P73 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for HNRNPA1P73. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HNRNPA1P73 shows higher tumor expression in BRCA, LUAD, LIHC and KIRC. The BRCA box plot shows higher HNRNPA1P73 RNA expression in tumor versus normal tissue (log2 FC = +0.074, t-test p < 0.001).
This table shows molecular features associated with HNRNPA1P73 in patient tissues and cancer cell lines. In patient samples, HNRNPA1P73 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
